Radiolabeled peptides and other ligands for receptors overexpressed in tumor cells for imaging neoplasms

Nuclear Medicine and Biology

Volumn 23, Issue 6, 1996, Pages 673-676

  McAfee, John G ^a   Neumann, Ronald D ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

radiolabeled ligands; radiolabeled peptides; tumor cell receptors

Indexed keywords

ARGIPRESSIN; CYTOKINE; ENDOTHELIN; ESTROGEN; GALANIN; GASTRIN RELEASING PEPTIDE; GROWTH FACTOR; INDIUM 111; INTERMEDIN; IODINE 123; LIGAND; METIROSINE; OCTREOTIDE; PEPTIDE; SOMATOSTATIN; SUBSTANCE P; TECHNETIUM 99M; VASOACTIVE INTESTINAL POLYPEPTIDE;

CONFERENCE PAPER; ISOTOPE LABELING; RECEPTOR BINDING; TUMOR SCINTISCANNING;

EID: 0030221012     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/0969-8051(96)00068-6     Document Type: Conference Paper

References (36)

1. 1. Abrams M. J., Juweid M., ten Kate C. I., Schwartz D. A., Hauser M. M., Gaul F. E., Fuccello A. J., Rubin R. H., Strauss H. W. and Fischman A. J. (1990) Technetium-99m-human polyclonal IgG radiolabelled via the hydrazino nicotinamide derivative for imaging sites of infection in rats. J. Nucl. Med. 31, 2022-2028.
2. 2. Baidoo K. E., Lever S. Z. and Scheffel U. (1994) Bifunctional chelator for facile preparation of neutral technetium complexes. Bioconjug. Chem. 5, 114-118.
3. 3. Brown R. S. and Wahl R. L. (1993) Overexpression of Glut-1 glucose transporter in human breast cancer. Cancer 72, 2979-2985.
4. 4. Csaplàr K., Langen K.-J., Mühlensiepen H., Kiwit J. C. W., Holschback M., Stöcklin G. and Müller-Gärtner H.-W. (1995) Investigation of I-125-α-methyltyrosine and I-125-α-methyl-a-methyltyrosine uptake in glioma cell cultures [Abstract]. Eur. J. Nucl. Med. 22, 866.
5. 5. Cserháti T. and Szögi M. (1995) Review: Role of hydrophobic and hydrophilic forces in peptide-protein interaction: new advances. Peptides 16, 165-173.
6. 6. Cuttitta F. (1993) Peptide amidation: Signature of bioactivity. Anat. Rec. 236, 87-93.
7. 7. Daughaday W. H. (1990) Editorial: The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinol 127, 1-4.
8. 8. Delpassand E., Yang D. J. and Cherif A. (1995) Synthesis, biodistribution and estrogen receptor scintigraphy of In-111 DTPA tamoxifen analog [Abstract]. J. Nucl. Med. 36, 161P.
9. 9. Gansow O. A. (1991) Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. Nucl. Med. Biol. 18, 369-381.
10. 10. Hennig I. M., Laissue J. A., Horisberger U. and Reubi J. C. (1995) Substance P receptors in human primary neoplasms: Tumoral and vascular localization [Abstract]. J. Nucl. Med. 36, 71 P.
11. 11. Hoffman T. J., Sieckman G. I. and Volkert W. A. (1995) Targeting small cell lung cancer using iodinated peptide analogs [Abstract]. J. Label. Cmpd. Radiopharm. 37, 321-323.
12. 12. Humphries M. J., Olden K. and Yamada K. M. (1986) A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 233, 467-470.
13. 13. Iwanoto Y., Robey F. A., Graf J., Sasaki M., Kleinman H. K., Yamada Y. and Martin G. R. (1987) YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 238, 1132-1134.
14. 14. Jensen R. T. and Coy D. H. (1991) Progress in the development of potent bombesin receptor antagonists. Trends Pharmacol. Sci. 12, 13-19.
15. 15. John C. S., Bowen W. D., Saga T., Kinwya S., Vilner B. J., Baumgold J., Paik C. H., Reba R. C., Neumann R. D., Varma V. M. and McAfee J. G. (1993) A malignant melanoma imaging agent: Synthesis, characterization, in vitro binding and biodistribution of Iodine-125-(2-piperidinylaminoethyl) 4-iodobenzamide. J. Nucl. Med. 34, 2169-2175.
16. 16. John C. S., Vilner B. J. and Bowen W. D. (1995) Synthesis, binding characteristics and in vivo clearance of 4(I-125) PEMP: A sigma receptor ligand for imaging tumors [Abstract]. J. Nucl. Med. 36, 6P.
17. 17. Katzenellenbogen J. A. A. (1995) Designing steroid receptor-based radiotracers to image breast and prostate tumors. J. Nucl. Med. 36, 8S-13S.
18. 123I Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20, 716-731.
19. 19. Lehninger A. L. (1970) Biochemistry: The Molecular Basis of Cell Structure and Function (pp. 67-87). Worth Publishers, New York.
20. 20. Mease R. C., Srivastava S. C., Meinken G. E. and Steplewski Z. (1989) Cyclohexylpolyamino-carboxylates may produce improved indium-111-immunoconjugates for tumor imaging [Abstract]. J. Nucl. Med. 30, 934.
21. 21. McDonnell D. P., Clemm D. L. and Imhof M. D. (1994) Definition of the cellular mechanisms, which distinguish between hormone and anti-hormone activated steroid receptors. Semin. Cancer Biol. 5, 327-336.
22. 22. McDonnell D. P., Vegeto E. and Gleeson M. A. G. (1993) Review: Nuclear hormone receptors as targets for new drug discovery. Biotechnology 11, 1256-1261.
23. 23. Mertens J., Terriere D. and Bowmon R. (1994) The radiosynthesis of a new potential glucose transport protein tracer: 3-[125I] iodophloretin. J. Label. Compd. Radiopharm. 34, 1011-1021.
24. 24. Michelot J. M., Moreau M. F. C., Veyre A. J., Bonafous J. F., Bacin F. J., Madelmont J. C., Bussiere F., Souteyrand P. A., Mauclaire L. P., Chossat F. M., Papon J. M., Labarre P. G., Kauffmann Ph. and Plagne R. J. (1993) Phase II scintigraphic clinical trial of malignant melanoma and metastases with Iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide). J. Nucl. Med. 34, 1260-1266.
25. 25. Moody T. W. and Cuttitta F. (1993) Miniview: Growth factor and peptide receptors in small cell lung cancer (bombesin analogs). Life Sci. 52, 1161-1173.
26. 26. Mueckler M. (1994) Facultative glucose transporters. FEBS Eur. J. Biochem. 219, 713-725.
27. 27. Prevost G., Mormont C., Gunning M. and Thomas F. (1993) Therapeutic use and perspectives of synthetic peptides in oncology. Acta Oncol. 32, 209-215.
28. 28. Scofield P. A. (Ed). (1992) The Insulin-Like Growth Factors: Structure and Biological Functions. Oxford University Press, Oxford and New York.
29. 123I-labelled interleukin-2. Eur. J. Endocrinol. 131, 431-437.
30. 123I-labelled interleukin-2: Labeling procedure and animal studies. Nucl. Med. Commun. 13, 713-722.
31. 31. Van Hagen P. M., Breeman W. A. P., van den Anker-Lugtenburg E. J., ten Bokum A. M. C., Visser T. J. and Krenning E. P. (1995) Thymus scintigraphy with [In-111-DTPA-Argl] substance P [Abstract]. J. Nucl. Med. 36, 207P.
32. 32. Virgolini I., Raderer M., Kurtaren A., Angelberger P., Banyai S., Yang Q., Li S., Banyai M., Pidlich J., Niederle B., Scheithauer W. and Valent P. (1994) Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N. Engl. J. Med. 331, 1116-1121.
33. 33. VonFeldt J. M., Monfardini C., Fish S., Rosenbaum H., Kieber-Emmons T., Williams R. M., Khan S. A., Weiner D. B. and Williams W. V. (1995) Development of GM-CSF antagonist peptides. Peptide Res. 8, 20-32.
34. 34. Williams W. V. and Weiner D. B. (Eds.). (1993) Biologically Active Peptides: Design, Synthesis and Utilization (Vol. 1). Technomic Publishing, Lancaster, Pennsylvania.
35. 35. Wraight E. P., Bard D. R., Maughan T. S., Knight C.G. and Page-Thomas D. P. (1992) The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma. Br. J. Radiol. 65, 112-118.
36. 36. Ying S. W., Niles L. P. and Crocker C. (1993) Human malignant melanoma cells express high affinity receptors for melatonin: Antiproliferative effects of melatonin and 6-chloromelatonin. Eur. J. Pharmacol. 246, 89-96.